Skip to content
Voruciclib
Voruciclib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target cyclin-dependent kinase 2, dual specificity tyrosine-phosphorylation-regulated kinase 1B, LIM domain kinase 1, dual specificity mitogen-activated protein kinase kinase 2, cyclin-dependent kinase 6, glycogen synthase kinase-3 alpha, cyclin-dependent kinase 1, cyclin-dependent kinase 9, cyclin-dependent kinase 8, glycogen synthase kinase-3 beta, casein kinase I isoform gamma-1, cyclin-dependent kinase 4, serine/threonine-protein kinase pim-1, and cyclin-dependent kinase 5.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
5 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C802————2
Myeloid leukemia acuteD015470C92.01————1
B-cell chronic lymphocytic leukemiaD015451C91.11————1
Follicular lymphomaD008224C821————1
Mantle-cell lymphomaD020522C83.11————1
Large b-cell lymphoma diffuseD016403C83.31————1
Hematologic neoplasmsD0193371————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVORUCICLIB
INNvoruciclib
Description
Voruciclib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target cyclin-dependent kinase 2, dual specificity tyrosine-phosphorylation-regulated kinase 1B, LIM domain kinase 1, dual specificity mitogen-activated protein kinase kinase 2, cyclin-dependent kinase 6, glycogen synthase kinase-3 alpha, cyclin-dependent kinase 1, cyclin-dependent kinase 9, cyclin-dependent kinase 8, glycogen synthase kinase-3 beta, casein kinase I isoform gamma-1, cyclin-dependent kinase 4, serine/threonine-protein kinase pim-1, and cyclin-dependent kinase 5.
Classification
Small molecule
Drug classcyclin dependent kinase inhibitors (formerly-cidib)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CC[C@@H](c2c(O)cc(O)c3c(=O)cc(-c4ccc(C(F)(F)F)cc4Cl)oc23)[C@@H]1CO
Identifiers
PDB—
CAS-ID1000023-04-0
RxCUI—
ChEMBL IDCHEMBL3905910
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDW66XP666AM (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
CDK2
CDK2
DYRK1B
DYRK1B
LIMK1
LIMK1
MAP2K2
MAP2K2
CDK6
CDK6
GSK3A
GSK3A
CDK1
CDK1
CDK9
CDK9
CDK8
CDK8
GSK3B
GSK3B
CSNK1G1
CSNK1G1
CDK4
CDK4
PIM1
PIM1
CDK5
CDK5
Organism
Homo sapiens
Gene name
CDK2
Gene synonyms
CDKN2
NCBI Gene ID
1017
Protein name
cyclin-dependent kinase 2
Protein synonyms
cdc2-related protein kinase, Cell division protein kinase 2, p33 protein kinase
Uniprot ID
P24941
Mouse ortholog
Cdk2 (12566)
cyclin-dependent kinase 2 (P97377)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 83 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details